Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stachowicz K et al. – At the same time, ritanserin, the 5–HT2A/C receptor antagonist, did not change the anxiolytic–like effects of ACPT–I. The results of these studies indicate that the GABA–ergic and serotonergic systems are involved in the potential anxiolytic action of ACPT–I.

Related Articles

Additional evidence for the affective dimension of dyspnea in patients with COPD
Research in Nursing & Health, 11/24/09    Relevance Score: 93%

Anxiety and depressive disorders in offspring at high risk for anxiety: A meta-analysis
Journal of Anxiety Disorders, 11/19/09    Relevance Score: 93%

Relationships of Fear, Anxiety, and Depression With Physical Function in Patients With Knee Osteoarthritis
Archives of Physical Medicine and Rehabilitation, 11/06/09    Relevance Score: 92%

Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care
Family Practice, 11/04/09    Relevance Score: 92%

Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients
Multiple Sclerosis, 11/18/09    Relevance Score: 91%

Today in Neuro/Psych pharmacology...keeping you current

Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up
Acta Neurologica Scandinavica, 12/14/09

Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial)
Movement Disorders, 12/14/09

Vitamin E Use Is Associated with Improved Survival in an Alzheimer’s Disease Cohort
Dementia and Geriatric Cognitive Disorders, 12/14/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address